WALTHAM, Mass., Nov. 21 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), announced today that it closed its previously announced public offering on Tuesday. The Company sold a total of 13,634,302 shares in the offering at a public offering price of $61.49 per share. The total number of shares sold by the Company included 1,800,000 shares sold to the underwriters upon their exercise of their over-allotment option in full. Certain selling stockholders of the Company also sold 165,698 shares of common stock in the offering. The net proceeds to the Company from the offering were approximately $806.4 million.
UBS Investment Bank, Jefferies & Company, Inc. and Merrill Lynch & Co. are acting as joint book-running managers for the offering. Leerink Swann LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. The offering may be made only by means of a prospectus supplement and the accompanying prospectus. A copy of the prospectus supplement and accompanying prospectus related to this offering may be obtained by calling the Prospectus Department at UBS Investment Bank, 299 Park Avenue, New York, NY 10171, toll-free at 888-827-7275; Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY 10022 by phone at (212) 284-2342 or by fax request at (212) 284- 2208; or Merrill Lynch & Co., 4 World Financial Center, 250 Vesey Street, Ground Floor, New York, New York 10080 by phone at 212-449-1000.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
|SOURCE Inverness Medical Innovations, Inc.|
Copyright©2007 PR Newswire.
All rights reserved